Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally. Show more

2101 COTTONTAIL LANE, SOMERSET, NJ, UNITED STATES, 08873, Somerset, NJ, 08873, USA

https://legendbiotech.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

3.646B

52 Wk Range

$16.24 - $39.27

Previous Close

$18.85

Open

$19.24

Volume

2,834,303

Day Range

$18.52 - $19.24

Enterprise Value

3.203B

Cash

646.4M

Avg Qtr Burn

-85.35M

Insider Ownership

1.25%

Institutional Own.

54.12%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details R/r Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (DVRd) Details Multiple myeloma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB2102 Details Cancer, Small cell lung cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUCAR-G39D (Allogeneic CAR-T) Details Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB2501 (In Vivo CAR-T) Details Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB1901 Details Cancer, T-cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.